Skip to main content
. 2021 Aug 31;32(1):124–132. doi: 10.1097/SLE.0000000000000992

TABLE 2.

Results of Adverse Events

Outcome of Interest Studies Participants Effect Estimate P I 2
All studies
 Cholangitis 7 520 2.17 [0.85, 5.54] 0.10 44%
 Bile leakage 8 375 0.71 [0.23, 2.15] 0.54 0%
 Pneumoperitoneum 5 374 0.86 [0.22, 3.35] 0.82 0%
 Bleeding 6 509 1.61 [0.63, 4.14] 0.32 0%
 Perforation 5 455 1.72 [0.46, 6.49] 0.42 0%
 Stent dysfunction 8 433 0.55 [0.30, 1.02] 0.06 0%
 Stent migration 7 340 0.79 [0.29, 2.14] 0.64 0%
 Stent obstruction 6 338 0.48 [0.21, 0.94] 0.04 0%
Studies with FCSEMS
 Cholangitis 3 99 10.29 [1.69, 62.74] 0.01 NS
 Bile leakage 5 141 0.44 [0.04, 4.49] 0.49 0%
 Pneumoperitoneum 2 135 0.72 [0.03, 18.08] 0.84 NS
 Bleeding 1 39 Not estimable NS NS
 Perforation 1 39 Not estimable NS NS
 Stent dysfunction 4 177 0.72 [0.25, 2.10] 0.55 0%
 Stent migration 3 61 0.73 [0.11, 5.07] 0.75 46%
 Stent obstruction 3 99 0.39 [0.09, 1.76] 0.22 0%

FCSEMS indicates fully covered self-expandable metal stent.